CN108290874A - 一种肾外髓质分泌钾通道抑制剂的可药用盐 - Google Patents

一种肾外髓质分泌钾通道抑制剂的可药用盐 Download PDF

Info

Publication number
CN108290874A
CN108290874A CN201780004197.8A CN201780004197A CN108290874A CN 108290874 A CN108290874 A CN 108290874A CN 201780004197 A CN201780004197 A CN 201780004197A CN 108290874 A CN108290874 A CN 108290874A
Authority
CN
China
Prior art keywords
solvent
angle
alcohols
mixed solvent
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780004197.8A
Other languages
English (en)
Other versions
CN108290874B (zh
Inventor
卢韵
邵启云
武乖利
冯君
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Original Drug Research And Development Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN108290874A publication Critical patent/CN108290874A/zh
Application granted granted Critical
Publication of CN108290874B publication Critical patent/CN108290874B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

提供一种肾外髓质分泌钾通道抑制剂的可药用盐，特别是其L‑酒石酸盐及其I型结晶和II型结晶。所述ROMK抑制剂的可药用盐，特别是L‑酒石酸盐提高了生物利用度和稳定性。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN201780004197.8A 2016-06-07 2017-06-06 一种肾外髓质分泌钾通道抑制剂的可药用盐 Active CN108290874B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610398233 2016-06-07
CN2016103982330 2016-06-07
PCT/CN2017/087326 WO2017211271A1 (zh) 2016-06-07 2017-06-06 一种肾外髓质分泌钾通道抑制剂的可药用盐

Publications (2)

Publication Number Publication Date
CN108290874A true CN108290874A (zh) 2018-07-17
CN108290874B CN108290874B (zh) 2021-07-27

Family

ID=60577585

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780004197.8A Active CN108290874B (zh) 2016-06-07 2017-06-06 一种肾外髓质分泌钾通道抑制剂的可药用盐

Country Status (11)

Country Link
US (1) US11059810B2 (zh)
EP (1) EP3466945A4 (zh)
JP (1) JP2019517494A (zh)
KR (1) KR20190015305A (zh)
CN (1) CN108290874B (zh)
AU (1) AU2017277002B2 (zh)
BR (1) BR112018073368A2 (zh)
CA (1) CA3024727A1 (zh)
MX (1) MX2018014759A (zh)
TW (1) TW201742866A (zh)
WO (1) WO2017211271A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109879863A (zh) * 2017-12-06 2019-06-14 江苏恒瑞医药股份有限公司 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018380171A1 (en) * 2017-12-06 2020-07-09 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of renal outer medullary potassium channel inhibitor and preparation method thereof
TW202045170A (zh) * 2019-02-28 2020-12-16 大陸商江蘇恒瑞醫藥股份有限公司 一種含有腎臟鉀離子外排通道抑制劑的藥物組合物及其製備方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459216A (zh) * 2009-05-06 2012-05-16 默沙东公司 肾外髓质钾通道的抑制剂
WO2014085210A1 (en) * 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN104540826A (zh) * 2012-07-26 2015-04-22 默沙东公司 用作肾外髓钾通道的抑制剂的螺稠合的哌啶衍生物
WO2016091042A1 (zh) * 2014-12-08 2016-06-16 江苏恒瑞医药股份有限公司 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
JP2014101353A (ja) * 2012-10-26 2014-06-05 Shionogi & Co Ltd オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物
WO2015065866A1 (en) * 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459216A (zh) * 2009-05-06 2012-05-16 默沙东公司 肾外髓质钾通道的抑制剂
CN104540826A (zh) * 2012-07-26 2015-04-22 默沙东公司 用作肾外髓钾通道的抑制剂的螺稠合的哌啶衍生物
WO2014085210A1 (en) * 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016091042A1 (zh) * 2014-12-08 2016-06-16 江苏恒瑞医药股份有限公司 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109879863A (zh) * 2017-12-06 2019-06-14 江苏恒瑞医药股份有限公司 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法
CN109879863B (zh) * 2017-12-06 2020-10-20 江苏恒瑞医药股份有限公司 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法

Also Published As

Publication number Publication date
US11059810B2 (en) 2021-07-13
CN108290874B (zh) 2021-07-27
BR112018073368A2 (pt) 2019-03-06
TW201742866A (zh) 2017-12-16
EP3466945A1 (en) 2019-04-10
JP2019517494A (ja) 2019-06-24
AU2017277002A1 (en) 2018-11-22
CA3024727A1 (en) 2017-12-14
MX2018014759A (es) 2019-03-11
KR20190015305A (ko) 2019-02-13
WO2017211271A1 (zh) 2017-12-14
AU2017277002B2 (en) 2021-01-21
EP3466945A4 (en) 2019-11-06
US20200123135A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
JP5086069B2 (ja) 重硫酸アタザナビルおよび新規形態の製造方法
EP0870767B1 (en) 1-(5-isoquinolinesulfonyl)homopiperazine hydrochloride hydrates
TWI518072B (zh) 塔適那偉（ａｔａｚａｎａｖｉｒ）硫酸氫鹽之製法及其新穎的形式
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
KR100437307B1 (ko) 토라세미드의 새로운 결정 변형태 ⅲ
CN108290874A (zh) 一种肾外髓质分泌钾通道抑制剂的可药用盐
US20070238759A1 (en) Novel Polymorph V of Torasemide
BRPI0415010B1 (pt) Formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida
EP1833810B1 (de) Kristalline modifikationen von n-alpha-(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino-(l)-phenylalanin-4-ethoxycarbonylpiperazid und/oder salzen davon
JP2002500223A (ja) Ａ形と呼称される結晶変態でのドキサゾシンメシラートの製造法およびその製造のための中間生成物
AU2006319985B2 (en) Acid addition salt of dihydropyridine derivative
WO2024125361A1 (zh) N-取代苯基磺酰胺类化合物的固体形式
US20220098186A1 (en) Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
US7449584B2 (en) N-(2((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide Crystalline Form 1
EP2239265A1 (en) Crystalline cinnamide compounds or salts thereof
JP2008290989A (ja) ジヒドロピリジン誘導体の酸付加塩を含有する医薬
AT5463U1 (de) Amlodipinhemimaleat
JPH0971582A (ja) １−（５−イソキノリンスルホニル）ホモピペラジン塩酸塩１／２水和物
DE20116391U1 (de) Amlodipinhemimaleat

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1255568

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220701

Address after: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee after: Jiangsu original drug research and Development Co., Ltd

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

TR01 Transfer of patent right